Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease

David L. Hemsell, Bertis B. Little, Sebastian Faro, Richard L Sweet, William J. Ledger, Alan S. Berkeley, David A. Eschenbach, Pal Wölner-Hanssen, Joseph G. Pastorek

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

This six-center, prospective, open-label clinical trial compared the efficacy and safety of three regimens recommended by the Centers for Disease Control and Prevention (CDC) for the treatment of women hospitalized for acute pelvic inflammatory disease (PID). The study focused on the response to inpatient therapy, not on long-term prevention of sequelae. A severity score was used for objective comparison of the degree of illness before and after therapy. Women were randomly assigned (in a 1:1:1 ratio) to treatment with cefoxitin plus doxycycline, clindamycin plus gentamicin, or cefotetan plus doxycycline. Two hundred seventy-five (94.2%) of 292 evaluable women required no alteration in therapeutic regimen. The three regimens produced almost identical cure rates. No serious adverse clinical or laboratory events were observed. In short, the three regimens recommended by the CDC for inpatient therapy of acute PID were similarly effective and safe.

Original languageEnglish (US)
Pages (from-to)720-727
Number of pages8
JournalClinical Infectious Diseases
Volume19
Issue number4
StatePublished - Oct 1994

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease'. Together they form a unique fingerprint.

  • Cite this

    Hemsell, D. L., Little, B. B., Faro, S., Sweet, R. L., Ledger, W. J., Berkeley, A. S., Eschenbach, D. A., Wölner-Hanssen, P., & Pastorek, J. G. (1994). Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clinical Infectious Diseases, 19(4), 720-727.